1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine
• 英文别名: [(2~{R})-2-oxidanyl-3-[oxidanyl-[2-(trimethyl-$l^{4}-azanyl)ethoxy]phosphoryl]oxy-propyl] hexadecanoate；2-[[(2S)-3-hexadecanoyloxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C₂₄H₅₁NO₇P
• 分子量: 496.645
• InChiKey: ASWBNKHCZGQVJV-QHCPKHFHSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  33
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine 、 N-boc-1-甲基-L-色氨酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 生成
  参考文献：
  名称：

  NANO-ENABLED IMMUNOTHERAPY IN CANCER

  摘要：

  在某些实施例中，提供了一种用于促进免疫疗法治疗癌症的平台技术。在某些实施例中，提供了一种纳米载体，可促进与细胞死亡诱导剂（ICD诱导剂）一起传递IDO抑制剂。在某些实施例中，IDO抑制剂与脂质双层的组分结合形成纳米囊泡。在另一实施例中，提供了一种方法和组合物，其中ICD诱导剂（例如多柔比星、奥沙利铂、米托蒽醌等）和IDO途径抑制剂（例如IDO抑制剂前药）被整合到一个纳米载体（例如脂质双层（LB）包被的纳米粒子）中，从而实现对原位胰腺癌部位的全身传递。

  公开号：

  US20200197534A1

文献信息

• Multifunctional Liposome: A Bright AIEgen-Lipid Conjugate with Strong Photosensitization
  作者：Xiaolei Cai、Duo Mao、Can Wang、Deling Kong、Xiamin Cheng、Bin Liu

  DOI：10.1002/anie.201809641

  日期：2018.12.10

  systems for cancer therapy. However, it is difficult to track traditional liposome delivery systems in an efficient and stable fashion to assess their delivery efficacy and biodistribution after administration. Meanwhile, conventional fluorescent liposomes containing optical tracers face the challenge of aggregation‐caused quenching. Herein, we report a strategy for the integration of an aggregation‐induced

  脂质体已经被用作用于癌症治疗的流行的药物递送系统。然而，难以以有效和稳定的方式追踪传统脂质体递送系统以评估其在给药后的递送功效和生物分布。同时，包含光学示踪剂的常规荧光脂质体面临着聚集引起的猝灭的挑战。本文中，我们报道了一种将聚集诱导的发射氟与脂质体整合以产生称为“ AIEsome”的AIEgen-脂质缀合物的策略。AIEsome表现出鲜红色的荧光以及出色的光稳定性和生物相容性，可用于体外癌细胞标记和体内肿瘤靶向。同时，得益于AIEgen出色的光敏能力以及在水性介质中的良好氧气暴露，
• DUAL-PURPOSE PAT/ULTRASOUND CONTRAST AGENT BOUND WITH NANOPARTICLES CONTAINING DRUG AND METHOD FOR PREPARING SAME
  申请人：IMGT Co, Ltd.

  公开号：EP3120872B1

  公开（公告）日：2021-06-09
• Means and Methods for the Treatment and Prevention of Allergic Diseases
  申请人：Braxmeier Tobias

  公开号：US20090018105A1

  公开（公告）日：2009-01-15

  The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization. Preferred in this context are edelfosine and miltefosine. In a particularly preferred embodiment, the present invention relates to the use of miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma.
• METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS
  申请人：BRAXMEIER Tobias

  公开号：US20110263531A1

  公开（公告）日：2011-10-27

  The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization and/or activation. Preferred in this context are Edelfosine, Miltefosine and Perifosine. In a particularly preferred embodiment, the present invention relates to the use of Miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma, atopic dermatitis and mastocytosis.
• METHODS FOR PROMOTING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS
  申请人：ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  公开号：US20200261591A1

  公开（公告）日：2020-08-20

  The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.